AbbVie Inc.

🇺🇸New York Stock Exchange
Back to all articles
AbbVie Inc. stock analysis ABBV overview
Bullish +75

AbbVie (ABBV) Stock Jumps on Strong Q1 Beat and Upgraded Full-Year Forecast

📈 AbbVie reported first-quarter adjusted earnings of $2.65 per share, beating analyst estimates of $2.59.

💰 Total quarterly revenue reached $15 billion, representing a 12% year-over-year increase.

🚀 The immunology division grew by 16%, while the neuroscience segment surged by 26%.

💊 Skyrizi and Rinvoq drove growth with revenue increases of 31% and 23% respectively.

⚠️ Strong performance from new products offset a 39% revenue decline in Humira due to biosimilar competition.

📈 ABBV shares rose 2.5% in premarket trading following the positive earnings announcement.

🔭 The company raised its full-year 2026 adjusted EPS forecast to $14.08–$14.28.

🤝 Upgraded guidance reflects management confidence in the immunology and neuroscience portfolios.

⚖️ GAAP net income declined year-over-year to $0.39 per share due to excluded expenses not captured in adjusted metrics.

📉 Despite the stock recovering some losses, it still faces a 13% year-to-date decline.

🧠 Neuroscience is establishing itself as an increasingly important revenue source for the company.

🔁 Adjusted earnings of $2.65 mark the second consecutive quarter of year-over-year improvement.

Bullish Signals
  • AbbVie reported first-quarter adjusted earnings of $2.65 per share, surpassing the analyst consensus estimate of $2.59 and climbing from $2.46 in the same period last year.
  • Quarterly revenue reached $15 billion, representing a strong 12% year-over-year increase that beat the $14.72 billion analyst projection.
  • The immunology division grew by 16%, driven by Skyrizi's 31% revenue increase and Rinvoq's 23% growth, successfully offsetting the decline in the Humira franchise.
  • The neuroscience segment delivered an impressive 26% quarterly surge, demonstrating successful diversification beyond the immunology business.
  • Management raised its full-year 2026 adjusted EPS forecast to a range of $14.08–$14.28, upgrading from the previous $13.96–$14.16 range and placing the midpoint above Wall Street consensus.
  • Shares of ABBV gained 2.5% in premarket trading to reach $202.63 as investors responded favorably to the earnings beat and upgraded guidance.
  • AbbVie has achieved two consecutive quarters of year-over-year adjusted earnings improvement, with Q1 results decisively beating the prior-year figure.
Risk Factors
  • Despite strong earnings, AbbVie shares are still down 13% year-to-date as of Tuesday's market close, indicating significant recent investor skepticism or broader market headwinds.
  • The company faces a severe structural risk from Humira, which saw a steep 39% revenue drop as it loses market share to competitive biosimilar alternatives.
  • On a GAAP basis, quarterly net income totaled only $695 million ($0.39 per diluted share), representing a significant year-over-year decline compared to the prior year's $1.29 billion.
  • Full-year 2026 adjusted EPS guidance of $14.08–$14.28 places the company right at or near Wall Street consensus estimates, leaving little room for error given the high valuation implied by recent premarket gains.
  • The stock needs to make up considerable lost ground from its 13% year-to-date decline before any short-term momentum translates into sustained value.
Full Analysis
AbbVie (ABBV) shares rallied in premarket trading after the company reported a strong first-quarter beat, exceeding analyst expectations for both earnings per share and revenue. First-quarter adjusted EPS came in at $2.65 per share against a consensus of $2.59, while total revenue reached $15 billion, marking a 12% year-over-year increase above the estimated $14.72 billion. This positive momentum allowed the stock to climb 2.5%, helping it recover some ground following a 13% decline for the year-to-date period as of Tuesday's close. The financial outperformance was driven significantly by growth in specific business segments, with the immunology division expanding by 16% and the neuroscience division surging 26%. Within immunology, Skyrizi and Rinvoq acted as primary growth drivers, posting 31% and 23% revenue increases respectively. These robust performances from these newer drugs helped more than offset a steep 39% revenue drop associated with Humira, the company's former blockbuster medication that is facing increased competition from biosimilar alternatives. Looking ahead, AbbVie increased its full-year 2026 adjusted EPS forecast to a range of $14.08–$14.28, up from the previous projection of $13.96–$14.16. This upward revision reflects management's growing confidence in sustained performance from its immunology and neuroscience portfolios, placing the new guidance midpoint modestly above the current Wall Street consensus of $14.12. On a GAAP basis, quarterly net income totaled $695 million, or $0.39 per diluted share, which was lower than the year-ago quarter due to non-operating expenses included in the calculation, though adjusted metrics tell a different story of improvement with two consecutive quarters of year-over-year growth.